Apogee Therapeutics secured up to $1.3 billion in non-dilutive capital from Blackstone Life Sciences to advance zumilokibart (zumi) into Phase 3 for atopic dermatitis, with potential expansion into other inflammatory indications. The financing includes up to $800 million in royalty funding tied to clinical and regulatory milestones and up to $500 million in senior corporate debt. Apogee said it received immediate access to $100 million, with additional tranches unlocking based on Phase 3 enrollment completion and data thresholds, and a larger portion held back until FDA approval. The company linked the funding to its ongoing clinical evidence, including 16-week induction results reported for Part B of the Phase II APEX trial. Blackstone’s involvement underscores continued investor preference for late-stage de-risking via non-dilutive structures in dermatology. Apogee positioned the strategy as funding “to commercialisation and profitability” while preserving equity. The operational focus now shifts to Phase 3 execution, regulatory interaction, and payor discussions for a long-acting anti-IL-13 candidate.